Home > Healthcare > Medical Devices > Diagnostic Devices > pulmonary fibrosis biomarkers market
Get a free sample of Pulmonary Fibrosis Biomarkers Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Pulmonary Fibrosis Biomarkers Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The pulmonary fibrosis biomarkers industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. Companies are developing innovative biomarkers to aid in disease diagnosis, prognosis, and treatment monitoring. These biomarkers range from genetic markers to protein expression profiles, reflecting the complex nature of pulmonary fibrosis. Key factors driving competitiveness include the accuracy, specificity, and reproducibility of biomarkers, as well as their potential to guide personalized treatment strategies. Regulatory approvals and collaborations with research institutions further influence market positioning.
Some of the eminent market participants operating in the pulmonary fibrosis biomarkers industry include:
Biocartis NV, Biogen Inc, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd, Galapagos NV, Lung Therapeutics, Inc., Myriad Genetics, Inc, OptiKira LLC, Respivant Sciences GmbH, and Veracyte, Inc , are some of the major pulmonary fibrosis biomarkers companies worldwide.
North America pulmonary fibrosis biomarkers industry recorded USD 1.7 billion in 2023 due to the presence of a highly advanced healthcare infrastructure with well-established hospitals, research institutions, and diagnostic laboratories in the region.
The imaging test segment recorded USD 1.7 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to imaging tests complementing biomarker analysis and providing a comprehensive view of disease status.
Pulmonary fibrosis biomarkers market size was USD 4.1 billion in 2023 and is expected to reach over USD 6 billion by 2032 owing to the increasing advancements in biomarker discovery technology worldwide.